Facebook icon Twitter icon Forward icon

New edition of hospital hypos guideline published

A guideline for managing hypos in hospitals has been updated to reflect changes to soft drinks on the back of the forthcoming sugar tax.

The guidance published by the Joint British Diabetes Societies (JBDS) for Inpatient Care has been revised to factor in changes to the sugar content of beverages, including Lucozade and Ribena. To read more, click here

US doctors group calls for new type 2 HbA1c target

New guidelines for the desired HbA1c levels for people with type 2 diabetes have been recommended in the US.

The American College of Physicians (ACP) recommendations are part of an evidence-based guidance statement published in the Annals of Internal Medicine. To read more, click here.

Basal insulin initiation in type 2 diabetes guidelines published

Guidance for effective initiation and titration of basal insulin in type 2 diabetes has been published by a panel of experts from Canada.

Published by the Diabetes Therapy journal, it was developed by a multidisciplinary panel to address frequently asked questions on basal insulin initiation and titration. To read more, click here

JBDS-IP guidelines ‘being well used’

Guidelines set up to support and propose standards of care among secondary care organisations are “being well used” according to a national group that represents diabetes consultants in the UK.

The Joint British Diabetes Societies for Inpatient Care group (JBDS – IP) provides high-quality evidence-based guidelines and the organisation wanted to investigate how often its content was being downloaded from the Association of the British Clinical Diabetologists (ABCD) website. To read more, click here

Type 2 drug canagliflozin shown to lower heart failure risk

Adults with type 2 diabetes beginning treatment with canagliflozin may have a lower risk for hospital admissions for heart failure, acute myocardial infarction, ischemic stroke or haemorrhage stroke, according to a study.

US researchers compared them with those beginning treatment with DPP-IV inhibitors, GLP-1 receptor agonists or sulfonylureas.

To read more, click here